Literature DB >> 8525072

Treatment of patients with severe head injury by triamcinolone: a prospective, controlled multicenter clinical trial of 396 cases.

T Grumme1, A Baethmann, D Kolodziejczyk, J Krimmer, M Fischer, B von Eisenhart Rothe, R Pelka, H Bennefeld, E Pöllauer, H Kostron.   

Abstract

The present studies were conducted to test whether the outcome of severe head injury is improved by early administration of the synthetic corticosteroid triamcinolone. In a prospective, double-blind, multicenter clinical trial, 396 patients with severe head injury were randomized to a steroid group (n = 187) receiving 200 mg triamcinolone acetonide (Volon A soluble) i.v. within 4 h after trauma, followed by 3 x 40 mg/day i.v. for 4 days, and 3 x 20 mg/day i.v. for a further 4 days, and a placebo group (n = 209) receiving injections which did not contain any active drug. The placebo group was subjected to the same standard treatment procedures. Clinical features were not different between the groups upon admission to hospital. Subdural hematoma, epidural hematoma, and focal supratentorial contusion were among the most frequent diagnoses. The result of treatment with triamcinolone was assessed at discharge from the hospital and at 1 year after trauma, using the Glasgow Outcome Scale. Differences in favor of steroid treatment could be detected with regard to the patients' condition at discharge (P = 0.0634). More patients with steroids had a good recovery (49.2% vs 40.7%), and fewer died (16.0% vs 21.5%). Differences in outcome were even more pronounced (P < 0.0145) in patients with a focal lesion and a Glasgow Coma Score on admission of < 8 (n = 93). In this group, 34.8% of the patients made a good recovery, as against 21.3% of the placebo group; mortality was also lower in the verum group (19.6% vs 38.3%). The results indicate that a major subgroup of patients with severe head injury benefits from early administration of triamcinolone. Efficacy of the treatment can be expected, in particular, in patients with a focal cerebral lesion and a Glasgow Coma Score of < 8 on admission. Administration of steroids beginning at the scene of an accident would therefore be beneficial in these cases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8525072     DOI: 10.1007/bf02576791

Source DB:  PubMed          Journal:  Res Exp Med (Berl)        ISSN: 0300-9130


  12 in total

Review 1.  Critical appraisal of neuroprotection trials in head injury: what have we learned?

Authors:  Christos M Tolias; M Ross Bullock
Journal:  NeuroRx       Date:  2004-01

Review 2.  Multimodality monitoring in severe traumatic brain injury: the role of brain tissue oxygenation monitoring.

Authors:  Jamin M Mulvey; Nicholas W C Dorsch; Yugan Mudaliar; Erhard W Lang
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

Review 3.  A State-of-the-Science Overview of Randomized Controlled Trials Evaluating Acute Management of Moderate-to-Severe Traumatic Brain Injury.

Authors:  Peter Bragge; Anneliese Synnot; Andrew I Maas; David K Menon; D James Cooper; Jeffrey V Rosenfeld; Russell L Gruen
Journal:  J Neurotrauma       Date:  2016-03-18       Impact factor: 5.269

Review 4.  Corticosteroids for acute traumatic brain injury.

Authors:  P Alderson; I Roberts
Journal:  Cochrane Database Syst Rev       Date:  2005-01-25

Review 5.  [Shock trauma room management of the multiple-traumatized patient with skull-brain injuries. A systematic review of the literature].

Authors:  M Heinzelmann; H-G Imhof; O Trentz
Journal:  Unfallchirurg       Date:  2004-10       Impact factor: 1.000

Review 6.  Clinical trials in traumatic brain injury: past experience and current developments.

Authors:  Andrew I R Maas; Bob Roozenbeek; Geoffrey T Manley
Journal:  Neurotherapeutics       Date:  2010-01       Impact factor: 7.620

Review 7.  Neuroprotection Trials in Traumatic Brain Injury.

Authors:  Shamik Chakraborty; Brett Skolnick; Raj K Narayan
Journal:  Curr Neurol Neurosci Rep       Date:  2016-04       Impact factor: 5.081

8.  Multifaceted Mechanisms of WY-14643 to Stabilize the Blood-Brain Barrier in a Model of Traumatic Brain Injury.

Authors:  Winfried Neuhaus; Tobias Krämer; Anja Neuhoff; Christina Gölz; Serge C Thal; Carola Y Förster
Journal:  Front Mol Neurosci       Date:  2017-05-26       Impact factor: 5.639

9.  Imatinib treatment reduces brain injury in a murine model of traumatic brain injury.

Authors:  Enming J Su; Linda Fredriksson; Mia Kanzawa; Shannon Moore; Erika Folestad; Tamara K Stevenson; Ingrid Nilsson; Maithili Sashindranath; Gerald P Schielke; Mark Warnock; Margaret Ragsdale; Kris Mann; Anna-Lisa E Lawrence; Robert L Medcalf; Ulf Eriksson; Geoffrey G Murphy; Daniel A Lawrence
Journal:  Front Cell Neurosci       Date:  2015-10-07       Impact factor: 5.505

10.  Do corticosteroids play a role in the management of traumatic brain injury?

Authors:  Reid Hoshide; Vincent Cheung; Lawrence Marshall; Ekkehard Kasper; Clark C Chen
Journal:  Surg Neurol Int       Date:  2016-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.